Objective: The Patient-Centered Outcomes Research Institute (PCORI) uses a unique approach to Merit Review that includes patients and stakeholders as reviewers with scientists, and includes unique review criteria (patient-centeredness and active engagement of end users in the research).
Introduction
Clinical research funders rely heavily on external review of applications for funding to identify methodologically rigorous, high-impact research. Yet, experts have questioned the ability of traditional scientific review processes to identify novel, important research [1, 2] , and examinations of associations between review scores, and bibliometric indicators are mixed such that some studies find associations [3] [4] [5] [6] [7] and others fail to demonstrate relationships [8] [9] [10] [11] [12] [13] . The existing evidence should be interpreted in light of a recognition that correlations between review scores and biblimotric indicators may not be valid tests of peer review for a variety of reasons [14] and calls for evaluation of review processes using metrics of impact beyond bibliometrics [10, 15] . Nevertheless, finding ways to ensure optimal selection of promising research via peer review of funding applications is critical to effective allocation of limited research funds.
Inclusion of nonscientists such as patients and other health care stakeholders (e.g., clinicians, health systems administrators, policymakers, caregivers) who are poised to apply research findings in their decision making on review panels has been proposed as a way to improve identification of high-impact projects. Specifically, by bringing to the review process expertise that complements that of researchers, patients and health care stakeholders are expected to identify research that is both feasible and relevant to those who would use the findings in their decision making [16, 17] . However, research examining the impact of patient and stakeholder reviewers on review process and outcomes is sparse [18, 19] , and concerns have been raised about the rigor of review with nonscientists included and the assessment of scientific methods in inclusive reviews [16, 18, 20] .
The Patient-Centered Outcomes Research Institute (PCORI) was established to fund patient-centered comparative clinical effectiveness research (CER) [21] relevant to patients and other health care decision makers and that can be quickly applied in health decision making. Although much of PCORI's competitive review process, begun in 2012, is similar to those of other major clinical research funders ( Fig. 1) , PCORI also added unique elements for its Merit Review to meet imperatives of patientcentered outcomes research. PCORI includes patient-centeredness and engagement of patients and other stakeholders as distinct review criteria, along with technical merit, impact of the condition, and likelihood to improve health care and outcomes. Another unique feature is inclusion of patients and stakeholders as primary reviewers for every application. Although other funders have incorporated patients, consumers, or the public in their reviews [20, [22] [23] [24] [25] , the extent to which PCORI involves nonscientists in application review is unprecedented.
PCORI has examined its Merit Review since the inaugural cycle [16] and early findings demonstrated that scientists, patient, and stakeholder reviewers' final review scores converged through in-person discussion of applications. This examination of a limited sample indicated that PCORI funded a different set of projects after a second review that involved scientists, patients, and stakeholders together, than would have been funded by the first review including only scientists. Results suggest that patient and other stakeholders influence merit review results, but more evidence from more review cycles is needed to understand the influence more clearly as well as to permit future investigation of the relationship between this review model and success in funding high-impact research. Thus, this study examined review scores from multiple subsequent PCORI Merit Review cycles to assess the extent to which views from different types of reviewers influence review scores and funding outcomes. This study also assessed the relative emphasis placed on technical (scientific) merit compared to other criteria by a multistakeholder panel. Finally, to assess the effect of the in-person panel discussion on subsequent application scoring as one indicator of influence of reviewers, we examined the effect of the in-person discussion on reviewer scores and on agreement among different reviewer types.
PCORI Review Process
Applications to Broad PCORI Funding Announcements (PFAs; aligned with the 5 National Priorities for Research [26] ) undergo preliminary review by two scientists, one patient, and one stakeholder based on the PCORI Merit Review criteria and Methodology Standards [27, 28] (Fig. 1) . Reviewers are recruited into mutually exclusive groups based on the following definitions: "Patients" include those with or at risk of a condition, unpaid caregivers to someone affected by illness, and those serving in a patient advocacy role. "Stakeholder" reviewers include clinicians, purchasers, payers, representatives from industry, representatives from health systems, policymakers, or staff from clinical training institutions [29] .
Over time, PCORI has implemented multiple process improvements to enhance process quality and reduce burden for applicants and reviewers. For the current study sample, the process was as follows: Reviewers first independently evaluate applications to provide written critiques of strengths and weaknesses, and assign criterion scores from 1 (Exceptional) to 9 (Poor) and preliminary overall scores. Scientists are required to score all five criteria; patient and stakeholder reviewers are required to score three criteria: potential to improve care, patient-centeredness, and engagement. The top scoring applications (approx. 50%, based on average preliminary overall scores) are discussed at in-person panel meetings comprising approximately 50% scientists, 25% patients, and 25% stakeholders. After in-person discussion, all panel members provide a final overall score. Funding recommendations were made by PCORI staff and finalized by the PCORI Board of Governors based on Merit Review feedback, portfolio balance, and programmatic fit.
Methods

Design
This is an observational study using administrative data from PCORI Merit Review approved by the Chesapeake Institutional Review Board (IRB; formerly MaGil IRB, at the time of this work). This article follows reporting guidelines for observational studies [30] .
Sample and Data Collection
This study includes applications submitted to PCORI funding announcements for PCORI's scientific priority programs, excluding applications to the program with sole emphasis on methods research (Accelerating Patient-Centered Outcomes Research and Methodological Research). Applications submitted for special one-time funding opportunities, were excluded because they use different review criteria. Score data were obtained for the five recent review cycles (November 2013-August 2015 cycle) using the same review criteria and processes (see Supplemental Digital Content 1 for cycle timing).
Analysis
Statistical analyses were conducted using SAS/STAT software and R.
Descriptive Statistics and Correlations
Criterion scores means and variances were examined by review cycle and reviewer type for the pre-panel reviews. To use comparable variances between the reviewer types (given the reviewer type ratio of 2 scientists: 1 patient: 1 stakeholder) one of the two scientists reviewers' scores was randomly selected for each application for each review criterion in the descriptive Figure 1 . PCORI Merit Review Overview (pertains to review of applications to the Broad funding announcements).
analyses. Additional descriptive analyses using both scientist scores were examined and means were similar to the one randomly selected procedure (data not shown). Pearson correlations were examined among the review criteria by reviewer type and across reviewer types using all reviewer scores (2 scientists, 1 patient, and 1 stakeholder per application) to evaluate the magnitude of the relationship between the scores before statistical modeling.
Linear Regression Models
Among applications discussed at the in-person panels, three multiple linear regression models were used to assess relationships between review criterion scores and the average final postpanel overall score for each reviewer type (scientist, patient, or stakeholder). Outcome measures were the average overall inperson score for all in-person reviewers of a given reviewer type, and predictor variables were individual review criterion scores for all three reviewer types (five for scientists and three each for patients and stakeholders). Models were stratified by reviewer type; all models were adjusted for funding program, review cycle, and principal investigator characteristics including any/none NIH funding, any/none clinical degree(s), and years of experience since terminal degree (1-4,5-9, or 10þ).
Sensitivity Analyses
Two approaches were used to test the sensitivity of the multiple linear regression models. First, we constructed random effects linear regression models nested within review cycles based on the possibility that applications within a review cycle are more similar to each other than those in other cycles. Second, random forest plots provided "importance" indicators of the predictor variables that demonstrated the degree to which the prediction error increases when a specific predictor is altered and all other variables stay the same [31] . Random forest plots have been shown to avoid issues of overfitting, nonlinearity, collinearity, and violation of assumptions [32] [33] [34] .
Logistic Regression Models
Logistic regression analysis was used to assess associations between review criterion scores from each reviewer type (predictor variables) in relation to funding status (yes/no, dependent variable) among both all applications reviewed and limited to those applications discussed at the in-person panel with adjustment for program, review cycle, and characteristics of the principal investigator (same as linear regression models).
Change in Review Scores
To assess the impact of the in-person panel discussion on application scoring, we assessed the magnitude and direction of change in overall scores from online pre-panel to post-panel (final overall score minus preliminary overall score, negative change scores indicate scores improved) overall and by reviewer type. We used t-tests to determine whether mean change scores were significantly different from 0 and to assess differences between reviewer types. We also calculated the proportion of final overall review scores that changed by 1 or 2þ points on the 9-point scale from initial online scoring across all reviewers and by reviewer type. Both of the individual scores from the two scientists scoring each panel were included in this analysis.
Post-Discussion Score Agreement
Agreement or convergence of scores after the in-person discussion, compared to scores reviewers provide alone before group discussion, is one indicator of influence of reviewers on one another, although full convergence is not expected given intention to capture distinct perspectives by reviewer type. Two approaches were used to assess agreement across reviewer type in application scoring. First, Bland-Altman plots were used to assess agreement on overall scores across reviewer types both before and after the in-person discussion. Bland-Altman plots describe the level of agreement between two continuous measures (e.g., scores by scientist and patient reviewers) and graphically depict the difference in two measures (along the y-axis) against the average of those two measures (along the x-axis). When the measures are in perfect agreement (that is, no difference), all points lie along a horizontal line at Y ¼ 0. Dotted lines denote a 2 SD range above and below the mean difference, within which we would expect 95% of differences in scores to lie [35, 36] .
Second, to determine the extent to which reviewer types agree on which applications best meet the PCORI review criteria as measured by the final score, we examined how frequently the same application was ranked in the top tier by different reviewer types. Based on the distribution of scores within each review cycle individually, we determined which applications were ranked in the top 20% based on scientist reviewers' final overall scores and then assessed the proportion of those applications also in the top 20% of applications for patient and stakeholder reviewers.
Results
Descriptive Statistics and Correlations
Forty-two review panels reviewed 1312 applications across the four scientific priority areas in this analysis. Of those, 51% were discussed at the in-person panels and 9% were funded (Table 1) . These applications were reviewed by a total of 535 reviewers (254 scientists, 139 patients, and 142 stakeholders). Community affiliation is known for 81% of patient reviewers and for 57% of stakeholder reviewers. Of the patient reviewers with known affiliation, 73% identified as a patient, caregiver, or family member of a patient and 35% identify as a patient or caregiver advocate (categories not mutually exclusive). For stakeholder reviewers with known affiliation, 38% identified as clinicians or clinician associations, 35% identified as researchers, 14% were hospital or health systems representatives, 11% were affiliated with training institutions, 9% identified as other unspecified stakeholder groups, 6% were health care payers, 5% were from industry (pharmaceutical, device, or diagnostic manufacturer or developer), 24% were policymakers, and 1% were purchasers (categories not mutually exclusive).
The mean pre-discussion overall score was 45.6 (range 15.0-87.5) among the 1312 applications reviewed, with mean scores of 35.3 among applications that were discussed (N ¼ 663) and 56.1 among those not discussed (N ¼ 649). Pre-discussion overall scores were higher (worse) for scientists than for other reviewer types (scientists mean Criterion means and variances were relatively similar among scientists, patients, and stakeholders (Table 2) . Review criteria scores between the two preliminary scientist reviewers for each application were all positively correlated (all P o 0.001, ranging from 0.19 for impact of the condition to 0.40 for patient and stakeholder engagement). Within each reviewer type, the PCORI review criteria were all positively correlated (range 0.39-0.76, all P o 0.001). Among all reviewer types the highest estimated correlations were between patient-centeredness and stakeholder engagement (r ¼ 0.72-0.76). Scatterplots with Loess curves (locally
weighted linear regression curves that smooth the data) demonstrated that the relationships among criteria within reviewer types are generally linear (see Supplemental Digital Content 2). Ratings of the same criterion by different types of reviewers were also all positively correlated (range 0.12-0.36, all P o 0.001; Table 2 ).
Associations between Review Criterion Scores and Final Overall Scores
At least one merit review criterion score from each of the three reviewer types was associated with final review scores for all reviewer types (Table 4 ). The strongest predictor of final overall scores for all reviewer types was scientists' ratings of technical merit. Both the multilevel models including clustering within review cycle and the Random Forest Plots yielded similar findings (data not shown).
Associations between Review Criterion Scores and Funding Decisions
Among applications discussed at the panel, odds ratios for applications being funded were significantly related to scientists' ratings of potential to improve health care and outcomes, technical merit and patient centeredness; patient ratings of potential to improve health care and outcomes; and stakeholder ratings of potential to improve health care and outcomes (Table 4) . More favorable pre-discussion ratings by each reviewer type were associated with greater likelihood of funding. Results were similar for the model examining all applications (data not shown).
Changes in Review Scores
Across all cycles, overall scores changed (either increased or decreased) by 1 point 31% of the time, by 2þ points 26% of the time, and stayed the same 44% of the time (Table 3) . When scores changed, 79% of the time the score changed to a poorer (higher) score. All reviewer types demonstrated changes in the overall score: 52%, 60%, and 62% of the time for scientists, patients, and stakeholders, respectively. Patients and stakeholders were more likely to have larger changes (42 points) in scores compared to scientists (33% and 30%, respectively, vs. 19%). The mean change in scores for all reviewer types was significantly different from 0 (all P o 0.001) and the mean change score was larger for patients 0.7 (1.8) and for stakeholders 0.8 (1.5) compared to scientists 0.5 (1.2) (P for patient vs. scientist ¼ 0.054 and P for stakeholder vs. scientist ¼ 0.003). Note. Four models were conducted, one each with overall score by reviewer type as the dependent variable and one model with funding decision as the dependent variable. In addition to all listed review criteria being included in each model, all models further adjusted for program, review cycle, and characteristics of the principal investigator including any/none NIH funding, any/none clinical degree(s), and years of experience since attaining terminal degree (1-4, 5-9, or 10þ). Mean scores were used for the two scientist reviewers for this analysis. * Overall score from all reviewers of a given type for the entire in-person panel.
† Review criteria scores from preliminary reviewers only. Applications were scored on a scale from 1, "Exceptional," to 9, "Poor." P for difference in mean change between scientist and patient reviewers ¼ 0.054. P for difference in mean change between scientist and stakeholder reviewers ¼ 0.0016. P for difference in mean change between patient and stakeholder reviewers ¼ 0.29.
* Score change ¼ in-person score -preliminary score. Negative values indicate the score improved and positive values indicate the score worsened. Both individual scores were used for the two scientist reviewers for this analysis.
very high or very poor scores. After the discussion, agreement was stronger, with the 95% limitations of agreement ranging from approximately 3.5 to -3.5, and the magnitude of agreement between reviewer types varied less across the score range. In addition, after discussion, there was a high level of overlap across reviewer types in the applications ranking in the top 20%. Among the 123 applications that ranked in the top 20% among scientist reviewers, 66% also ranked in the top 20% for patients, 74% also ranked in the top 20% for stakeholders, and 57% ranked in the top 20% for all three reviewer types.
Conclusions
This article provides new evidence about how scientist, patient, and stakeholder views are incorporated in the PCORI Merit Review of applications for research funding and may facilitate funding research that is more relevant to health care decision making. One or more criterion ratings from each of the three reviewer types were associated with the final merit review scores for all three reviewer types and also with funding decisions, suggesting that all reviewer types influence funding outcomes. Specifically, all reviewers' views of the potential to improve health care and outcomes, as well as scientists' ratings of technical merit and patient-centeredness, were critical to funding success. As with PCORI, other funders who involve patients or consumers in research application review have reported that reviewers feel that nonscientists bring an important perspective to the process, produce reciprocal learning across reviewer types, and allow the best science to be funded [16, 24, 26, 37] . The only other funder to quantitatively examine the impact of patient reviewers on review scores was unable to ascertain whether consumer participation affected scientist reviewer scoring and found that the average final overall scores were similar with or without consumer scores included [19] . However, consumer participation in the review process examined was much more limited both in terms of numbers of consumers and extent of their participation. PCORI Merit Review also includes nonpatient stakeholders, and, to our knowledge, the literature lacks other evidence regarding the incorporation of health care stakeholder types in research application review.
Of note is the relative stability across cycles in criterion means and intercorrelations, comparable to observations from NIH merit review [38, 39] . Although all reviewer types appear to influence PCORI Merit Review outcomes, scientists' ratings have the strongest influence. The best predictors of final overall scores for each type of reviewer were scientists' ratings of technical merit followed by the scientists' ratings of potential to improve health care and outcomes. These findings suggest that scientific rigor is important to all reviewer types. Despite concerns expressed about the level of emphasis on scientific rigor in a multistakeholder process [20] , these results suggest that, similar to review at the National Institute of Health (NIH) comprising all scientists [38, 40] , technical merit is a top priority in evaluating research applications at PCORI Merit Review. It is notable that the ratings from three different types of reviewers for the likelihood of findings to improve health care and outcomes were significantly associated with funding status, suggesting that each reviewer type adds unique information on the assessment of this criterion. The results may suggest reviewer prioritization of criteria, with likelihood to improve health care and outcomes necessary to demonstrate strongly at the application stage, but the potential for research engagement need not be fully realized at the application stage. PCORI's review criteria are new and unique, and the ways in which reviewers use them in their application evaluation warrants further study.
The small, positive correlations among preliminary review criterion scores across reviewer types suggest that although there is some agreement between reviewer types in their criteria ratings, each reviewer type contributes a unique perspective to the discussion. The in-person discussion plays an important role in PCORI review scores and views converge through the in-person discussion, such that agreement across different types of reviewers is greater after discussion. In this study, all reviewer types changed their overall score for more than half the applications reviewed. This frequency of score changes is similar to that reported by others with panels comprising scientists alone [41] . However, compared to PCORI's first review cycle [16] , in more recent cycles a greater proportion of scientist, patient, and stakeholder reviewers showed relatively large changes (2 points or more), suggesting that PCORI reviewers may have become more likely to incorporate the views of others with time and improvements to the process. The larger score changes observed for patients and stakeholder reviewers compared to scientists are consistent with the fact that most patient and stakeholder reviewers scored applications on three of the five criteria and likely incorporated more information from scientific reviewers in their post-panel overall score. Findings suggest reviewers work collaboratively through the in-person discussion, supported by separate self-report of PCORI reviewers about respect for different reviewer type views and influence among reviewer types [37] . Though PCORI Merit Review brings together diverse reviewers, after the panel discussion with consideration of a variety of viewpoints and factors, they tend to agree about which projects best meet PCORI criteria.
Several limitations of this study should be considered. Although score data provide one important information source, findings should be considered in the context of other sources, including reviewer self-reported experience (which we examined simultaneously to this study and report separately) [37] and written reviewer critiques. Although reviewers are identified by a single affiliation type for the purpose of Merit Review, many reviewers have multiple roles (e.g., researcher, patient, clinician, caregiver), making it difficult to fully attribute contributions to Merit Review strictly by stated reviewer role. Reviewers do not rescore the individual criteria after the in-person discussion; thus understanding of the factors driving changes in overall scores is limited. Further, because patients and stakeholders are not required to score technical merit and impact of the condition when reviewing applications for PCORI's Broad PFAs, less is known about patients' and stakeholders' individual views on how well applications meet these criteria. Because patients and stakeholders are required to score all five criteria, including technical merit, for PCORI's Pragmatic Clinical Studies program [28] , PCORI will have future opportunities to examine the influence of patients and stakeholders across all criteria. Use of the mean of the two scientist scores in the regression models restricts the variability between these two scores, potentially limiting identification of regression effects, and regression models do not address causal relationships. Examination of the impact of the in-person discussion cannot comprehensively address determinants of funding decisions, because PCORI funding decisions, while based heavily on Merit Review scores, are made with respect to additional factors (e.g., programmatic fit). Available studies of the impact of panel discussion from other funders are instructive [39, 41, 42] but comparisons should be made cautiously given differences between funders in the prominence of scores to funding decisions. Differences in review processes also may limit the generalizability of the current
findings. The conclusions here are limited to the questions we framed and the specific methods we used to address those questions. Examinations of the role of merit reviewers in funding determinations are few, and the data reported here offer many opportunities for additional learning. Future analyses could apply additional sophisticated techniques (e.g., Classification-andRegression Tree [CART], multilevel modeling, Structural Equation Modeling) to understand more fully the interplay of process, group, and individual factors affecting the contributions of different reviewer types to review scores and outcomes.
PCORI's approach to Merit Review is new and unique and warrants careful examination. This article adds to the evidence that patients and stakeholders meaningfully contribute to research application review. This study suggests that obtaining PCORI funding depends on scientific rigor and is related to criteria important to patients and other stakeholders. The influence of diverse types of reviewers on review outcomes has not been comprehensively characterized before this investigation. As the impact of the research PCORI funds is tracked, these data can support future analyses of the role of inclusion of diverse reviewer types in research application review on success funding high impact research, particularly in terms of speed of uptake of research results in health care decisions and improvements in health care delivery and outcomes.
